Treatment of Langerhans Cell Histiocytosis

  • Park B
  • Shin K
  • Kim H
  • et al.
N/ACitations
Citations of this article
32Readers
Mendeley users who have this article in their library.

Abstract

Langerhans' cell histiocytosis (LCH) is a disease characterised by pathologic accumulation and proliferation of histiocytes, cells from the monocyte-macrophage system, in various tissues and organs. In this retrospective study we analyzed patients charts treated in the Department of pediatric hematology and oncology at the University Hospital Zagreb with the diagnosis of LCH. Twenty-two children were diagnosed between January 1st 1996 and December 31st 2010, and all were treated with chemotherapy. 19 patients survived (86%) and the remaining 3 (14%), all under the age of 2 with multisystem disease, died. At the time of diagnosis 12 children (55%) presented with single-system disease, the most common were bone lesions in 8 children (36%). All children were treated according to protocols LCH-I and LCH -III. Eight children had mild complications of treatment and the disease itself. Diabetes insipidus remains in 4 children.

Cite

CITATION STYLE

APA

Park, B. M., Shin, K. H., Kim, H. W., & Kim, H. J. (1996). Treatment of Langerhans Cell Histiocytosis. Journal of the Korean Orthopaedic Association, 31(5), 1218. https://doi.org/10.4055/jkoa.1996.31.5.1218

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free